Iron deficiency is considered to be one of most prevalent forms of malnutrition, yet there has been a lack of consensus about the nature and magnitude of the health consequences of iron deficiency in populations. This paper presents new estimates of the public health importance of iron-deficiency anemia (IDA), which were made as part of the Global Burden of Disease (GBD) 2000 project. Iron deficiency is considered to contribute to death and disability as a risk factor for maternal and perinatal mortality, and also through its direct contributions to cognitive impairment, decreased work productivity, and death from severe anemia. Based on meta-analysis of observational studies, mortality risk estimates for maternal and perinatal mortality are calculated as the decreased risk in mortality for each 1 g/dl increase in mean pregnancy hemoglobin concentration. On average, globally, 50% of the anemia is assumed to be attributable to iron deficiency. Globally, iron deficiency ranks number 9 among 26 risk factors included in the GBD 2000, and accounts for 841,000 deaths and 35,057,000 disability-adjusted life years lost. Africa and parts of Asia bear 71% of the global mortality burden and 65% of the disability-adjusted life years lost, whereas North America bears 1.4% of the global burden. There is an urgent need to develop effective and sustainable interventions to control iron-deficiency anemia. This will likely not be achieved without substantial involvement of the private sector.
Introduction
Iron deficiency has long been considered a major form of malnutrition throughout the world, yet there has been a lack of consensus about the nature of the public health consequences of this widespread deficiency and which population groups deserve primary attention in terms of intervention [1] . However, many experts agree that in poverty-stricken populations, iron deficiency is not being adequately controlled by public health and nutrition interventions as they are currently implemented [2] . This paper presents new estimates of the public health importance of iron deficiency [3] , with some implications for where resources might best be focused, both in terms of research and interventions. These estimates were made as part of the latest round of the World Health Organization's (WHO) Global Burden of Disease 2000 project (GBD 2000) . Summary estimates have been published [4] and full reports are forthcoming.
Iron deficiency: results from GBD 2000
Within GBD 2000, iron deficiency was considered as one of several forms of malnutrition. For a detailed description of the methods and results, please see Stoltzfus et al. [3] . What follows here is a brief summary.
Conceptually, malnutrition-in this case iron deficiency-may cause death or disability either directly (i.e., direct sequelae) or by increasing the risk of death or disability from other causes (i.e., as a risk factor). For example, IDA directly causes impaired muscle function and physical performance [5] , but it acts as a risk factor for maternal mortality. That is, women do not die in childbirth from IDA; rather, IDA increases a woman's risk of dying from cardiac failure in childbirth.
Iron deficiency was considered to potentially contribute to death and disability through the following outcomes: child mortality, maternal mortality, peri-S100 natal mortality, fitness and productivity, cognitive impairment, and morbidity from infectious disease. Of these, infectious morbidity was subsequently dropped, because the substantial epidemiologic evidence available does not support a significant relationship between iron deficiency and incidence or severity of infectious disease [6] . For child mortality there was insufficient epidemiologic data to provide sound estimates for IDA as a risk factor. This is a significant lack in the literature, and it is important to realize that the evidence does not preclude an important relationship.
To derive the risk estimates for maternal and perinatal mortality, hemoglobin concentration was used as the risk factor because there are insufficient studies (indeed, for maternal mortality, no studies) that measure IDA specifically as the risk factor. It was then assumed that 50% of anemia was attributable to iron deficiency. A further assumption was that the risk relationship between mortality and all anemia was the same as the risk relationship between mortality and the iron deficiency component of the anemia.
Population figures and anemia prevalence data were provided by the WHO, and are shown for the world and selected developing regions of the world in table 1. Anemia prevalence is highest in young children, followed by women. Data for other population groups are not shown here but are available in Stoltzfus et al. [3] .
Mortality-risk estimates associated with pregnancy hemoglobin levels were derived from meta-analysis of 6 published studies of maternal mortality and 10 published studies of perinatal mortality. For both outcomes, the studies included in the analysis varied in their geographic location and included populations with and without endemic malaria. For perinatal mortality, there was evidence that the risk relationship was stronger in African studies than in studies from other locations, and, therefore, an Africa-specific risk estimate was used. Data from two recent studies were used to estimate the likely magnitude of bias in the summary estimates due to unmeasured factors. Based on this analysis, the risk estimates were attenuated by 20%. The final risk estimates are shown in table 2.
The GBD 2000 uses the disability-adjusted life year (DALY) as the summary measure of death and disability. The DALY measures years of life spent in less than full health. In the case of premature mortality, a full DALY is lost for each of year of expected life lost. For other disease states, a fraction of a DALY (i.e., disability weight) is assigned to each year lived with the disease, with the weight corresponding to the severity of the disease. In the case of IDA, premature mortality of mothers and children is one source of DALYs lost. Another is the disability weight assessed as a fraction of a DALY for each year lived with anemia or its associated cognitive and physical impairment.
Globally, 841,000 deaths and 35,057,000 DALYs are attributable to IDA (table 1). The relationship between Table 1 . Population, anemia prevalence in risk groups, and death and disability attributable to iron-deficiency anemia in the world and in selected developing regions of the world [3] maternal pregnancy anemia and perinatal mortality is responsible for the largest contribution to both deaths and DALYs, representing 56% of the total [3, 4] . The global distribution of the disease burden of IDA is heavily concentrated in Africa and WHO region Southeast Asia-D (table 1) . These regions bear 71% of the global mortality burden and 65% of the DALYs lost. By contrast, the DALYs lost to IDA in North America and Cuba amount to 1.4% of the global total. It is an important (but not surprising) message that there is enormous inequity in the burden of iron deficiency in the world. There is an equally enormous need for interventions that will work in the less-developed regions of the world.
Another interesting comparison between world regions is the relative importance of maternal and perinatal mortality, which derives entirely from pregnancy anemia, compared with the "direct consequences" of iron deficiency, which derive primarily from childhood IDA. This is shown graphically in figure 1. It is important to remember that the relative sizes of these regional "pies" are vastly different. In fact, if these pies were truly proportional in size, the pie representing North America and Cuba would be barely visible, at about 5% of the total pie for Africa. (Exact ratios can be calculated from table 1.) Nonetheless, these pie graphs demonstrate that the relative importance of the different consequences of IDA varies by context. In regions where mortality rates are high, pregnancy anemia rates are also almost invariably high, and these two combine to create very large burdens of perinatal and maternal mortality attributable to IDA during pregnancy. In Africa, 81% of the total DALYs derives from mortality associated with pregnancy anemia. This fraction is also high in Latin America (61%), Eastern Mediterranean-D (72%), and Southeast Asia-D (68%) (see table 1 for regional definitions). By contrast, in North America and Cuba, only 10% of total DALYs derives from pregnancy anemia, with the remaining 90% coming from the direct disabling sequelae of IDA. The same is true for European countries with very low mortality rates (data not shown). The resulting message is that as overall mortality rates decline, the relative importance of the direct sequelae (i.e., cognitive impairment and decreased work productivity) increases, while that of pregnancy anemia and its associated mortality decreases.
It is an important caveat that the GBD 2000 project likely underestimates the consequences of IDA in childhood for two important reasons. First, as stated above, data are lacking to estimate the risk relationship between IDA and childhood mortality, even though a true relationship might exist. Second, the DALY, being a measure of disease and disability, does not capture fully the developmental consequences of IDA in childhood, which mainly involve changes in function within the range of "normality." That is, IDA is associated with shifts in intelligence that mainly fall within the range of normal function, rather than clinical retardation. Economic measures of the consequences of IDA would tend to weight the effects of IDA on cognition and work productivity much more heavily than its effects on maternal and perinatal mortality [7] . Thus, it is extremely important to understand the measuring stick used in the GBD 2000. It is a measure of health consequences and only health consequences. (table 3) , iron deficiency ranks #9 overall in terms of DALYs lost, falling lower than underweight (#1), and slightly higher than zinc deficiency (#11) and vitamin A deficiency (#13). There is no excuse for the scientific and public health community to be complacent about iron deficiency. At the same time, GBD 2000 further illuminates important gaps in our knowledge about the consequences of iron deficiency. Evidence for the relationships between IDA and maternal and perinatal mortality needs to be strengthened by well-controlled prospective observational studies. Randomized trials are conceivable and would add greatly to the evidence base, but will likely not be placebo-controlled for ethical reasons. As previously mentioned, there is an urgent need for more evidence on the relationship between IDA and mortality in young children. Fortunately, research is in process to address this question.
Regarding the relationship of iron deficiency to child development, cognition, and work productivity, as described by Dr. Tomas Walter in the colloquium [8] , evidence is mounting that early iron deficiency significantly affects children's neural physiology and behavior [5] . Well-controlled observational studies show that IDA is associated with behavioral differences, developmental delays, and lower IQ and poorer school performance [9] . Two published randomized controlled trials of iron supplementation in early childhood have both shown benefits to children's development [10, 11] . There is a need for longitudinal studies of cohorts of children whose iron status in early childhood is well described, so that the long-term consequences of early deficits can be described in social, economic, and educational terms [12] .
There is also a need for further research that describes the effects of IDA on people's well-being and activities in social terms. Iron deficiency adversely affects work productivity of adults, and likely also affects voluntary activities [13] . A particularly salient area for future research is the effect of maternal IDA on well-being and care-giving capacities and behaviors in the postpartum period. These effects are difficult to characterize because of the numerous methods of coping that humans use to adapt to compromised health. Yet the implications for the lives of women and infants may be significant, and these studies are certainly within the reach of innovative social scientists.
These gaps in the evidence should not preclude advocacy and action. It is striking that while iron deficiency in developed countries is being controlled mostly through private sector actions-namely availability of iron-rich foods and iron-fortified weaning foods-the public sector is shouldering the burden of iron interventions in less-developed countries, and frankly is failing. During the colloquium, Nita Dalmiya informed us that UNICEF is the largest distributor of iron supplements in the world [14] . This is an untenable solution to the problem. The question is not only one of sustainability, because at this point there is little or no success to be sustained. A recent WHO progress report on malnutrition [15] stated: "Unfortunately, there has been little appreciable change over the last two decades in the high worldwide prevalence of IDA. Few active programmes in both developed and developing countries have succeeded in reducing iron deficiency and anaemia. Important factors contributing to the lack of progress include failure to recognize the causes of iron deficiency and anaemia, lack of political commitment to control it, inadequate planning of control programmes, insufficient mobilization and training of health staff, and insufficient community involvement in solving the problem." (p. 17) In the context of the industry-sponsored colloquium, two critical needs to address the burden of IDA were emphasized. First is the need for affordable, appealing products. Despite the high prevalence and large disability burden associated with early childhood anemia, affordable, high-quality, and appealing supplemental forms of iron designed for young children are generally not available in less-developed countries. Even UNICEF currently does not stock an iron supplement for young children. This has been a challenge because young children cannot safely swallow hard pills, and liquid supplements are bulky to ship and store and are relatively unstable chemically. Preparations designed to appeal to children also introduce the risk of toxic overdose, so issues of dose and packaging are critical from a safety standpoint. Innovations such as home fortificants [16] ("sprinkles"), spreads, "foodlets" [17] , and powdered beverages like the one developed by Procter & Gamble Co. [18] are potential solutions, if they can be made widely available at affordable prices.
Second, the public sector working through clinical distribution channels can only achieve targeted periods of supplementation of short duration (e.g., prenatal care). While these approaches are needed to create a safety net during high-risk periods, they cannot control the problem completely. As has been the case with North America, there needs to be private sector involvement; i.e., the opportunity for people to purchase dietary iron supplements or iron-fortified foods for consumption in high-risk periods (e.g., early childhood and pregnancy) and as needed throughout the life cycle. The need for private sector provision of dietary iron supplements is perhaps even more acute where governments are in financial and political crisis, or where the public sector functions poorly. Unfortunately, this is true for many of the least developed regions where the burden of IDA is greatest.
Recent ethnographic work on women's perceptions of anemia and anemia treatments in Pemba Island, Zanzibar supports this argument. Young [19] concluded that over-the-counter pharmacies are among the most empowering places for Zanzibari women to receive health care. In the context of a poorly functioning public health care system, small private pharmacies provide an alternative to irregular supplies from a government perceived as oppressive, because customers have immediate access to iron pills and are "no longer patients without any real bargaining power, at the mercy of potentially hostile or indifferent staff " [19, p. 110 ]. Furthermore, private pharmacies are generally convenient, require less waiting, are not dependent on uncertain donor aid, and provide a living for the owners. They appear to be a win-win situation for both the small business owner and women seeking care.
There is an important role to be played by companies that manufacture pharmaceutical and food products to develop high-quality, appealing, safe products that can be distributed through local markets. Such work is urgently needed to reduce the burden of disability and death associated with the present high prevalence of IDA.
